UK snubs Herceptin, Tykerb use with hormone drugs (Reuters, 15 December 2010)

15 Dec 2010


The UK drug licensing advisory body NICE has released new draft guidance on breast cancer drugs, showing that two drugs - Herceptin and Tykerb - should not be used in combination with aromatase inhibitors.

Full article


Related Topics

Adrenal Diabetes Metabolism Obesity Cardiovascular Bone Endocrine-Disrupting Chemicals Endocrine-Related Cancer Neuroendocrinology Reproduction Steroid and Steroidogenesis Thyroid

Share this story